FTO and central nervous system cancer: Recent studies also posit that D-2-HG treatment can inhibit glioma cell viability in a dose-dependent fashion (Supplementary Data, Su and colleagues, 2018) and that D-2-HG can inhibit FTO in IDH1mut acute myeloid leukemia cells to increase m6A abundance and slow cell proliferation (25, 26).